Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02751359 |
Recruitment Status :
Completed
First Posted : April 26, 2016
Results First Posted : May 12, 2021
Last Update Posted : May 12, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain | Drug: Cannabidiol Drug: Placebo | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Basic Science |
Official Title: | Characterization of the Analgesic Effects of Oral CBD in Healthy, Normal Volunteers |
Actual Study Start Date : | July 2016 |
Actual Primary Completion Date : | July 2017 |
Actual Study Completion Date : | April 2020 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Active CBD
Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
|
Drug: Cannabidiol
200, 400, or 800 mg Cannabidiol
Other Name: CBD |
Placebo Comparator: Placebo
On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
|
Drug: Placebo
0 mg Cannabidiol |
- Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test [ Time Frame: Baseline, 60 minutes, 120 minutes 180 minutes, 240 minutes, 300 minutes and 360 minutes after each dose ]Time to first feel pain ("Pain threshold" measured in seconds) during the Cold Pressor Test and withdraw the hand from the cold water ("Pain Tolerance" measured in seconds). Changes in threshold from baseline were averaged across study sessions for each CBD dose.
- Subjective Drug Effects Related to Abuse Liability as Measured by Visual Analog Scales [ Time Frame: 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, 270 minutes, 300 minutes, 330 minutes, 360 minutes ]Participants rate the strength of their desire to take again, drug liking, good effect and bad effect. Each item was presented and the participant was asked to rate his / her rating on a scale anchored by 'Not At All' (0 mm) to 'Extremely' (100 mm). The average of all timepoints is reported for each category.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Able to perform study procedures
- Women practicing an effective form of birth control
Exclusion Criteria:
- Female subjects who are currently pregnant or breastfeeding.
- Current illicit drug use
- Presence of significant medical illness
- History of heart disease
- Request for drug treatment
- Current parole or probation
- Recent history of significant violent behavior
- Major psychiatric disorder
- Current use of any prescription or over-the-counter medication
- Current pain
- Clinically significant Raynaud's syndrome

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02751359
United States, New York | |
Cooper | |
New York, New York, United States, 10013 |
Principal Investigator: | Ziva D Cooper, PhD | New York State Psychiatric Institute / CUMC |
Documents provided by Ziva D. Cooper, PhD, University of California, Los Angeles:
Responsible Party: | Ziva D. Cooper, PhD, Associate Professor of Clinical Neurobiology (in Psychiatry), University of California, Los Angeles |
ClinicalTrials.gov Identifier: | NCT02751359 |
Other Study ID Numbers: |
7009 |
First Posted: | April 26, 2016 Key Record Dates |
Results First Posted: | May 12, 2021 |
Last Update Posted: | May 12, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Cannabidiol Anticonvulsants |